Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature

Journal of Viral Hepatitis

Volumn 23, Issue 7, 2016, Pages 545-559

  Basnayake, S K ^a   Easterbrook, P J ^b  

^a SOUTHERN HEALTH   (Australia)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

global estimates; hepatitis B; hepatitis C; HIV co infection

Indexed keywords

CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CHRONICITY; GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION RATE; MIXED INFECTION; MORTALITY RATE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VIRUS LOAD;

EID: 85028243023     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12519     Document Type: Review

References (252)

1. World Health Organization. Health Statistics. Available at: http://www.who.int/topics/statistics/en/ (accessed 12 September 2014).
2. World Health Organization. Constitution of the World Health Organization. Available at: http://apps.who.int/gb/bd/PDF/bd47/EN/constitution-en.pdf?ua=1 (accessed 12 September 2014).
3. Director General of the World Health Organization. Technical meeting on global health estimates. Available at: http://www.who.int/dg/speeches/2013/health_estimates_20130213/en/ (accessed 12 September 2014).
4. World Health Organization, 2012. Prevention and control of viral hepatitis infection: framework for global action, 2012. Available at: http://www.who.int/csr/disease/hepatitis/GHP_Framework_En.pdf?ua=1 (accessed 8 November 2014).
5. Sixty-Seventh World Health Assembly. Agenda Item 12.3. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R6-en.pdf?ua=1 (accessed 8 November 2014).
6. 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2013; 385(9963): 117–171.
7. Lavanchy D. Hepatitis B: virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004; 11(2): 97–107.
8. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003; 39(Suppl 1): S64–S69.
9. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362(9401): 2089–2094.
10. Boesecke C, Wasmuth JC, Hepatitis B. In: Mauss S, Berg T, Rockstroh J, Sarrazin C, Wedemeyer H, eds. Hepatology: A Clinical Textbook, Germany: H. Flying Publisher, 2012: 32–43.
11. Bristol-Myers S.Hépatite B: mieux la connaître pour mieux la traiter. J Pediatr Pueric 2006; 19: 340–343.
12. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582e92.
13. Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol 2013; 8: 371–380.
14. World Health Organization. 2013, 2012, 2011, 2010, 2008. Hepatitis B. Fact sheet No. 204. Available at: http://www.who.int/mediacentre/factsheets/fs204/ (accessed 8 November 2014).
15. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol 2005; 34(Suppl. 1): S1–S3.
16. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30: 2212–2219.
17. World Health Organization. Hepatitis B vaccines. Weekly Epidemiological Record 2009 2009; 20–405.
18. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol2006; 44: S6–S9.
19. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529–538.
20. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227–242.
21. Murata K, Sugimoto K, Shiraki K, Nakano T. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection. World J Gastroenterol 2005; 11: 6848–6852.
22. Ou DP, Yang LY, Huang GW, Tao YM, Ding X, Chang ZG. Clinical analysis of the risk factors for recurrence of HCC and its relationship with HBV. World J Gastroenterol 2005; 11: 2061–2066.
23. Borgia G, Gentile I. Treating chronic hepatitis B: today and tomorrow. Curr Med Chem 2006; 13: 2839–2855.
24. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23: 512–520.
25. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34(6): 1225–1241.
26. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect Dis 2002; 2: 395–403.
27. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733–1745.
28. Ioannou GN. Chronic hepatitis B infection: a global disease requiring global strategies. Hepatology 2013; 58: 839–843.
29. Teo E-K, Lok ASF: Epidemiology, transmission, and prevention of hepatitis B virus infection. In Basow DS, ed. UpToDate. Waltham, MA: UpToDate, 2009.
30. Yahyaeftekhari E, Arababadi MK, Hakimi H, Zarandi ER. Common HBV genotype in southeastern Iranian patients. Arch Iran Med 2010; 13(2): 147–149.
31. Tosun SY, Yuceturk M, Benzergil S. The immunization of babies born of HBsAg positive pregnant women. Ege Tip Dergisi 2002; 41(1): 21–23.
32. British Liver Trust. A professional's guide to hepatitis B. 2009. Southampton Road and Ringwood, BH24 1HY.
33. Honer ZSC, Cornberg M. The role of HBsAg levels in the current management of chronic HBV infection. Ann Gastroenterol 2014; 27: 105–112.
34. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486–1500.
35. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118–1129.
36. Safioleas M, Lygidakis NJ, Manti C. Hepatitis B today. Hepatogastroenterology 2007; 54: 545–548.
37. Liu J, Fan D. Hepatitis B in China. Lancet 2007; 369: 1582–1583.
38. Weinbaum CM, Mast EE, Ward JW. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. Hepatol 2009; 14: S35–S44.
39. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005; 25(Suppl 1): 3–8.
40. Margolis HS, Coleman PJ, Brown RE, Mast EE. SheingoldSH, Arevalo JA. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 1995; 274: 1201–1208.
41. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2(8): 479–486.
42. Mast E, Margolis H, Fiore A, Brink E, Goldstein S, Wang S. A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of Infants, Children, and Adolescents. Atlanta, GA: Center for Disease Control, 2005: 1–23.
43. Hepatitis B. Information for Health Professionals- Perinatal Transmission. Atlanta, GA: Control Cf D, 2010.
44. Chen DS. Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 2009; 50: 805–816.
45. Centers for Disease Control and Prevention (CDC). Viral hepatitis. Available at: http://www.cdc.gov/hepatitis (accessed 10 September 2014).
46. Lok AS. Hepatitis B infection: pathogenesis and management. J Hepatol 2000; 32: 89–97.
47. Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis 2012; 16(2): 347–369.
48. Ghadir MR, Belbasi M, Heidari A et al. Distribution and risk factors of hepatitis B virus infection in the general population of Central Iran. Hepat Mon 2012; 12: 112–117.
49. Chen JD, Yang HI, Iloeje UH et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138(5): 1747–1754.
50. Almeida AM, Silva DI, Guerra AA Jr, Silva GD. Acurcio Fde A. Efficacy of interferon (conventional, pegylated) and lamivudine for treatment of chronic hepatitis B: a systematic review. Cad Saude Publica 2009 Aug; 25(9): 1667–1677.
51. Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health consensus development conference statement: management of hepatitis. Hepatology 2009; 49(Suppl. 5): S4–S12.
52. Papatheodoridis G, Buti M, Cornberg M et al. European Association for the study of the liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167–185.
53. Asfaw N, Zufan S, Girmay M. Prevalence of Hepatitis B surface antigen (HBsAg) among visitors of Shashemene General Hospital voluntary counselling and testing center. BMC Res Notes 2011; 9: 4–35.
54. Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J 2005; 2: 82.
55. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis 2010; 14: 1–21.
56. Rizzetto M. Hepatitis B vaccination: current status. Minerva Gastroenterol Dietol 1991; 45: 199–205.
57. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection – a global challenge. N Engl J Med 2012; 366: 1749–1752.
58. Bini EJ, Perumalswami PV. Hepatitis B virus infection among American patients with chronic hepatitis C virus infection: prevalence, racial/ethnic differences, and viral interactions. Hepatology 2010 Mar; 51(3): 759–766.
59. Brass V, Moradpour D. New insights into hepatitis B and C virus co-infection. J Hepatol 2009 Sep; 51(3): 423–425.
60. Crockett SD, Keeffe EB. Natural history and treatment of hepatitis B virus and hepatitis C virus coinfection. Ann Clin Microbiol Antimicrob 2005; 4: 13.
61. Tillman HL, Zachou K, Dalekos GN. Management of severe acute to fulminant hepatitis B: to treat or not to treat and when to treat. Liver Int 2012; 32(4): 544–553.
62. Tan J, Zhou J, Zhao P, Wei J. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 2012; 31: 1169–1175.
63. Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38(Suppl 2): 18–23.
64. Ioannou GN. Hepatitis B virus in the United States: Infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011; 154: 319–328.
65. Hepatitis B Foundation. Statistics. Available at: http://www.hepb.org/hepb/statistics.htm (accessed 12 September 2014).
66. Arababadi MK, Pourfathollah AA, Jafarzadeh A, Hassanshahi G, Rezvani ME. Association of exon 9 but not intron 8 VDR polymorphisms with occult HBV infection in south-eastern Iranian patients. J Gastroenterol Hepatol 2009; 25(1): 90–93.
67. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L. Hepatitis B: Epidemiology and prevention in developing countries. World J Hepatol 2012; 4: 74–80.
68. Chan HL-Y. Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. J Gastroenterol Hepatol 2011; 26: 8–12.
69. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50(3): 661–662.
70. Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147: 58–61.
71. Perrillo R. Benefits and risks of interferon therapy for hepatitis B. Hepatology 2009; 49: S103–S111.
72. Simard CW, Finelli EP, Fiore L, Bell AE, Hepatitis BP. B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28(1): 112–125.
73. Chan HL, Sung JJ. Hepatocellular carcinoma and hepatitis B virus. Semin Liver Dis 2006; 26(2): 153–161.
74. Public Health Agency of Canada. Canadian Immunization Guide: Hepatitis B Vaccine. Available at: http://www.phac-aspc.gc.ca/publicat/cig-gci/p04-hepb-eng.php (accessed 12 September 2014).
75. Loomba R, Rivera MM, McBurney R et al. The natural history of acute hepatitis C: clinical presentation, laboratory findings and treatment outcomes. Aliment Pharmacol Ther 2011; 33: 559–565.
76. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2007; 45: 507–539.
77. Kiire CF. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut 1996; 38(Suppl 2): S5–S12.
78. Leemans WF, Janssen HL, de Man RA. Future prospectives for the management of chronic hepatitis B. World J Gastroenterol 2007; 13: 2554–2567.
79. Thio CL. Hepatitis B and human immunodeficiency virus coinfection. Hepatology 2009; 2009(49): S138–S145.
80. McGovern BH. The epidemiology, natural history and prevention of hepatitis B: Implications of HIV coinfection. Antivir Ther 2007; 12: H3–H13.
81. Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, its genotypes and clinical associations of genotypes. Hepatol Res 2007; 37: S9–S19.
82. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008; 48: 353–367.
83. Hoffmann CJ, Thio CL. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007; 7: 402–409.
84. World Health Organization. Global surveillance control of hepatitis C, Report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35–47.
85. World Health Organization. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20–29.
86. World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341–344.
87. World Health Organization. Hepatitis C, 2003. Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html.
88. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333–1342.
89. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29(Suppl 1): 74–81.
90. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17(2): 107–115.
91. World Health Organization. 2014, 2013, 2012, 2011. Hepatitis C. Fact Sheet No. 164. Available at: http://www.who.int/mediacentre/factsheets/fs164/en/index (accesssed 8 November 2014).
92. World Health Organization. Viral hepatitis: report by the Secretariat. Geneva: World Health Assembly. 2010: 62.
93. World Health Organization. Global alert and response (GAR): hepatitis C. Available at: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html (accessed 17 April 2014).
94. World Health Organization: Department of Measurement and Health Information. December 2004. Available at: http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls (accesssed 8 November 2014).
95. World Health Organization. Viral Cancers. Available at: http://www.who.int/vaccine_research/diseases/viral_cancers/en/print.html (accessed 8 November 2014).
96. World Health Organization. World Hepatitis Day [internet] 28 July 2012, Disponível em. Available at: http://www.who.int/mediacentre/events/annual/world_hepatitis_day/en/ (accesssed 8 November 2014).
97. World Health Organization (WHO). Hepatitis C. Weekly epidemiological record: Geneva, WHO. 2011; 41: 445–456.
98. WHO Expert Committee. Prevention and Control of Schistosomiasis and Soil-Transmitted Helminthiasis. World Health Organ Tech Rep Ser 2002; 912: i–vi.
99. World Health Organization. Sixty-Third World Health Assembly Provisional Agenda Item (11.12, A63/15). Geneva Switzerland, : World Health Organization, 2010.
100. Shephard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet 2005; 5: 558–567.
101. Perz JF, Alter MJ. The coming wave of HCV-related liver disease: dilemmas and challenges. J Hepatol 2006; 44: 441–443.
102. Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007; 13: 2436–2441.
103. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705–714.
104. Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002 May; 2(5): 293–302.
105. Aoufi RS, García AR. Management of HCV infection in chronic kidney disease. Nefrologia 2011; 31: 260–267.
106. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962–973.
107. Chisari F. Unscrambling hepatitis C virus-host interactions. Nature 2005, 436: 930–932.
108. Brass V, Moradpour D. New insights into hepatitis B and C virus co-infection. J Hepatol 2009 Sep; 51(3): 423–425.
109. Torres H, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Rev Clin Oncol 2012; 9(3): 156–166.
110. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631–657.
111. Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin J Am Soc Nephrol 2009; 4: 207–220.
112. Kieffer TL, Kwong AD, Picchio GR. Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs). J Antimicrob Chemother 2010; 65(2): 202–212.
113. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Pardo M, Bartolome J, Carreno V. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006; 43(10): 1277–1283.
114. Poynard T, Yuen M-F, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362(9401): 2095–2100.
115. Fabrizi F, Martin P, Lunghi G, Ponticelli C. Nosocomial transmission of hepatitis C virus infection in hemodialysis patients: clinical perspectives. Int J Artif Organs 2000; 23: 805–816.
116. Neal KR, Ramsay S, Thomson BJ et al. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut 2007; 56: 1098–1104.
117. Negro F, Albertit A. The global health burden of hepatitis C virus infection. Liver Int 2011; 31: 1–3.
118. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562–1569.
119. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3(2): 41–46.
120. Fauvelle C, Lepiller Q, Felmlee DJ et al. Hepatitis C virus vaccines—progress and perspectives. Microb Pathog 2013; 58: 66–72.
121. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41–52.
122. Harnois DM. Hepatitis C virus infection and the rising incidence of hepatocellular carcinoma. Mayo Clin Proc 2012; 87: 7–8.
123. Jang JY, Chung RT. New treatments for chronic hepatitis C. Korean J Hepatol 2010; 16: 263–277.
124. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
125. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359–362.
126. Hadigan C, Kottilil S. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. JAMA 2011; 306: 294–301.
127. De Francesco R, Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005; 436: 953–960.
128. Perrella A, Vitiello L, Atripaldi L, Conti P, Sbreglia C, Altamura S. Elevated CD4 + /CD25 + T cell frequency and function during acute hepatitis C presage chronic evolution. Gut 2006; 55(9): 1370–1371.
129. Bostan N, Mahmood T. An overview about hepatitis C: a devastating virus. Crit Rev Microbiol 2010; 36: 91–133.
130. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553–562.
131. Tessema B, Yismaw G, Kassu A et al. Seroprevalence of HIV, HBV, HCV and syphilis infections among blood donors at Gondar University Teaching Hospital, Northwest Ethiopia: declining trends over a period of five years. BMC Infect Dis 2010; 10: 1–7.
132. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 356(14): 1445–1454.
133. Williams R. Global challenges in liver disease. Hepatology 2006; 44(3): 521–526.
134. Dibonaventura MD, Yuan Y, Lescrauwaet B et al. Multicountry Burden of Chronic Hepatitis C Viral Infection among Those Aware of their Diagnosis: A Patient Survey. PLoS ONE 2014; 9: e86070.
135. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60(2): 392–420.
136. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335–1374.
137. Idrees S, Ashfaq UA, Rab SA, Idrees N. Hepatitis C virus molecular biology, in vivo/in vitro model systems and current trends of therapies: a brief review. Open Access Sci Rep 2013; 2: 623.
138. Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55(1): 10–15.
139. Alberti A, Clumeck N, Collins S et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615–624.
140. Kottilil S, Yan MY, Reitano KN et al. Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology 2009; 50(1): 34–45.
141. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: asystematic review of longitudinal studies. J Viral Hepatitis 2006; 13(1): 34–41.
142. Pattullo V, Heathcote J. Hepatitis C and diabetes: one treatment for two diseases? Liver Int 2010; 30: 356–364.
143. Mitchell AE, Colvin HM. Palmer Beasley R. Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology 2010; 51: 729–733.
144. Kim CW, Chang KM. Hepatitis C virus: virology and life cycle. Clin Mol Hepatol 2013; 19(1): 17–25.
145. Pawlotsky JM. Treatment of chronic hepatitis C: current and future. Curr Top Microbiol Immunol 2013; 369: 321–342.
146. Mendez-Sanchez N, Uribe M. National consensus on hepatitis C. Conclusions. Rev Invest Clin 2002; 54: 55.
147. Baldo V, Baldovin T, Trivello R, Floreani A. Epidemiology of HCV infection. Curr Pharm Des 2008; 14: 1646–1654.
148. Lo RV3, Kostman JR. Management of chronic hepatitis C. Postgrad Med J2005; 81: 376–382.
149. Memon MI, Memon MA. Hepatitis C: An epidemiological review. J Viral Hepat 2002; 9: 84–100.
150. Gacche RN, Al-Mohani SK. Seroprevalence and risk factors for hepatitis C virus infection among general population in central region of Yemen. Hepat Res Treat 2012; 2012: 1–4
151. National Institutes of Health. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002 (June 10–12, 2002). Gastroenterology 2002; 123: 2082–2099.
152. Rustgi VD. The epidemiology of hepatitis C infection in the United States. J Gastroenterol 2007; 42: 513–521.
153. Sievert W, Altraif I, Razavi H, Abdo A, Ahmed A, Alomair A. A systematic review of hepatitis C virus epidemiology in Asia, Australia, and Egypt. Liver Int 2011; 31(Suppl 2): 61–80.
154. Kedziora P, Figlerowicz M, Formanowicz P et al. Computational methods in diagnostics of chronic hepatitis C. Bull Pol Ac Tech 2005; 53(3): 273–281.
155. National Institute of Allergy and Infectious Diseases. Hepatitis C. 2011. Available at: http://www.niaid.nih.gov/topics/hepatitis/hepatitisc/Pages/Default.aspx (accessed 12 December 2013).
156. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 47–52.
157. Lozano R, Naghavi M, Foreman K et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095–2128.
158. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271–278.
159. Mahboobi N, Agha-Hosseini F, Bagheri LK. Hepatitis C virus and lichen planus: the real association. Hepat Mon 2010; 10: 161–164.
160. The Global Burden of Hepatitis. C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20–29.
161. Hoofnagle JH. Hepatitis C, the clinical spectrum of disease. Hepatology 1997; 26: 15–20.
162. Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 41–46.
163. Pybus OG, Barnes E, Taggart R et al. Genetic history of hepatitis C virus in east Asia. J Virol 2009; 83: 1071–1082.
164. Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C infection. Host, viral and environmental factors. JAMA 2000; 284: 450–456.
165. Butt AA. Hepatitis C virus infection: the new global epidemic. Expert Rev Anti Infect Ther 2005; 3: 241–249.
166. Operskalski EA, Kovacs A. HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep 2011; 8(1): 12–22.
167. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240–247.
168. World Health Organization. The World Health Report 1996 – Fighting Disease, Fostering Development. Geneva: World Health Organization, 1996.
169. World Health Organization. WHO Report, 2002. Available at: http://www.who.int/emc (accessed 8 November 2014).
170. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28(1): 112–125.
171. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 2005; 34(6): 1329–1339.
172. Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med 2007; 12(3): 160–167.
173. Ke W, Liu L, Zhang C et al. Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis. PLoS ONE 2014; 9(6): 1–8.
174. Carey WD. The prevalence and natural history of hepatitis B in the 21st century. Clev Clin J Med 2009; 76: S2–S5.
175. Sonneveld MJ, Wong VWS, Woltman AM et al. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology 2012; 142(3): 513–520.
176. Almeida AM, da Silva DI, Guerra AA Jr, Silva GD, Acurcio FDA. Efficacy of interferon (conventional, pegylated) and lamivudine for treatment of chronic hepatitis B: a systematic review. Cadernos de Saude Publica 2009; 25(8): 1667–1677.
177. Silva MN, Bacellar P, Martins H, Aguiar MM. Hepatitis B—casuistic review of internal medicine outpatient consultations. Revista da Sociedade Portuguesa de Medicina Interna 2007; 14: 140–145.
178. European Association for the Study of the Liver. EASL–EORTC clinical practice guidelines: “management of hepatocellular carcinoma”. J Hepatol 2012; 56: 908–943.
179. Sorrell MF, Belongia EA, Costa J et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology 2009; 49(Suppl): S4–S12.
180. Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012; 1: 2–14.
181. Thursz M et al. Pathogenesis of chronic Hepatitis B. In: Chronic M, ed. Hepatitis B. London: Blackwell publishing, 2006.
182. Pierre TM, Chen ZM. The hepatitis B. Pathol Biol 2010; 58: 243–244.
183. Muszlak M, Lartigau-Roussin C, Farthouat L, Petinelli M, Hebert JC, Santiago J. Vaccination de l'enfant contre l'hépatite B à Mayotte, île franc¸aise des Comores. Arch Pediatr 2007; 14: 1132–1136.
184. Arababadi MK, Hassanshahi G, Yousefi H. HBV-DNA in hemodialysis patients infected by HCV. Saudi J Kidney Dis Transpl 2009; 20(3): 398–401.
185. Kuhns MC, Busch MP. New strategies for blood donor screening for hepatitis B virus: Nucleic acid testing versus immunoassay methods. Mol Diagn Ther 2006; 10(2): 77–91.
186. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis—United States, 2007. MMWR Surveil Summ 2009; 58(SS03): 1–27.
187. Margolis HS. Hepatitis B virus infection. Bull World Health Organ 1998; 76: 152–153.
188. Van Damme P, Ward J, Shouval D, Wiersma S, Zanetti A. Hepatitis B vaccines. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines, 6th ed. Philadelphia, PA, USA: Elsevier, 2012: 205–234.
189. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J Gastroenterol Hepatol 2011; 26(4): 628–638.
190. Hatzakis A, Wait S, Bruix J et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference. J Viral Hepat 2011; 18(Suppl 1): 1–16.
191. Dore GJ, Law M, MacDonald M, Kaldor JM. Epidemiology of hepatitis C virus infection in Australia. J Clin Virol 2003; 26: 171–184.
192. Ali SA, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis 2009; 13: 9–19.
193. World Health Organization. Progress Report, Global HIV/AIDS Response. Geneva: WHO; 2011. 2011. (Epidemic Update and Health Sector Progress towards Universal Access).
194. World Health Organization. Global Hepatitis Programme. Geneva: WHO, 2012.
195. UNAIDS. Joint United Nations Program on HIV/AIDS HIV and co-infections in people who inject drugs 2012. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/pcb/2012/20120612_Annette_Verster_presentation.pdf (accessed 8 November 2014).
196. UNAIDS. AIDS epidemic update: Special report on HIV/AIDS 2006. Available at: http://www.unaids.org/pub/EpiReport/2006.2006_EpiUpdate.en.pdf (accessed 8 November 2014).
197. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003; 23(2): 125–136.
198. Soriano V, Puoti M, Bonacini M et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV–HBV International Panel. AIDS 2005; 19: 221–240.
199. Zhou J, Dore GJ, Zhang F, Lim PL. Chen Y-MA. Hepatitis B and C virus coinfection in the TREAT Asia HIV observational database. J Gastroenterol Hepatol 2007; 22(9): 1510–1518.
200. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM et al. Liver related deaths in persons infected with the human immunodeficiency virus: the D:a:d study. Arch Intern Med 2006; 166: 1632–1641.
201. Puoti M, Airoldi M, Bruno R et al. Hepatitis B virus co-infection in HIV-infected subjects. AIDS Rev 2002; 4: 27–35.
202. Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected subjects. J Infect Dis 2003; 188: 571–577.
203. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593–601.
204. Larsen C, Pialoux G, Salmon D et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill 2008; 13: 1–4.
205. Re A, Michieli M, Casari S et al. High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009; 114: 1306–1313.
206. Koo YX, Tan DS, Tan IB, Tao M, Lim ST. “Anti-HBc alone” in human immunodeficiency virus-positive and immuno-suppressed lymphoma patients. World J Gastroenterol 2009; 15: 3834–3835.
207. Nyirenda M, Beadsworth MB, Stephany P et al. Prevalence of infection with hepatitis B and C virus and coinfection with HIV in medical inpatients in Malawi. J Infect 2008 Jul; 57(1): 72–77.
208. Diop-Ndiaye H, Toure-Kane C, Etard JF, Lô G, Diaw P, Ngom-Gueye NF, et al. Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 2008 Aug; 80(8): 1332–1336.
209. Lee HC, Ko NY, Lee NY, Chang CM, Ko WC. Seroprevalence of viral hepatitis and sexually transmitted disease among adults with recently diagnosed HIV infection in Southern Taiwan, 2000–2005: upsurge in hepatitis C virus infections among injection drug users. J Formos Med Assoc 2008 May; 107(5): 404–411.
210. Lacombe K, Bottero J, Lemoine M, Boyd A, Girard PM. HIV/hepatitis B virus co-infection: current challenges and new strategies. J Antimicrob Chemother 2009; 65: 10–17.
211. Thio C, Seaberg E, Skolasky RJ et al, and the Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet2002; 360: 1921–1926.
212. Benhamou Y. Update on the treatment of hepatitis B virus infection in patients infected by the human immunodeficiency virus. Med Mal Infec 2004; 34: 27–29.
213. Puoti M, Moioli MC, Travi G, Rosootti R. The burden of liver disease in HIV-infected patients. Semin Liver Dis 2012; 32: 103–113.
214. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34(6): 831–837.
215. UNAIDS. 2010 2010 AIDS Epidemic Update. Available at: http://www.unaidsorg/en/dataanalysis/epidemiology/ (accessed 12 September 2014).
216. Frederick T, Burian P, Terrault N et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDs 2009; 23(11): 915–923.
217. Chu C, Umanski G, Blank A, Meissner P, Grossberg R, Selwyn PA. Comorbidity-related treatment outcomes among HIV-infected adults in the Bronx NY. J Urban Health 2011; 88(3): 507–516.
218. Raymond HF, Hughes A, O'Keefe K, Stall RD, McFarland W. Hepatitis C prevalence among HIV-positive MSM in San Francisco: 2004 and 2008. Sex Transm Dis 2011; 38(3): 219–220.
219. Limketkai BN, Mehta SH, Sutcliffe CG et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308: 370–378.
220. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288(2): 199–206.
221. Thomas DL, Vlahov D, Solomon L et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74(4): 212–220.
222. Rockstroh JK, Mocroft A, Soriano V et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192(6): 992–1002.
223. Urbanus AT, van de Laar TJ, Stolte IG et al. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009; 23: F1–F7.
224. Ghosn J, Deveau C, Goujard C et al. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. Sex Transm Infect 2006; 82: 458–460.
225. Zeisel MB, Fofana I, Fafi-Kremer S, Baumert TF. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies. J Hepatol 2011; 54: 566–576.
226. Soriano V, Barreiro P, Nunez M. Management of chronic hepatitis B and C in HIV-coinfected patients. J Antimicrob Chemother 2006; 57: 815–818.
227. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M. Care of patients co-infected with HIV and HCV: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073–1089.
228. Macias J, Melguizo I, Fernández-Rivera F et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients on potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002; 21: 775–781.
229. Sungkanuparph S, Vibhagool A, Manosuthi W et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J Med Assoc Thai 2004; 87: 1349–1354.
230. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-Infected Person. Ann Intern Med 2003; 138: 197–207.
231. Hansen AB, Gerstoft J, Kronborg G, Larsen CS, Pedersen C, Pedersen G. Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS 2012; 26: 285–293.
232. Lo RV3, Volk J, Newcomb CW et al. Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/HIV Coinfection. Hepatology 2012; 56: 1688–1698.
233. Staples CT Jr, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 1999; 29: 150–154.
234. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS 2011; 6: 478–482.
235. Alatrakchi N, Koziel MJ. A tale of two viruses: hepatitis C in the age of HAART. Lancet 2003; 362: 1687–1688.
236. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res 2010; 85: 303–315.
237. Centers for Disease Control and Prevention. 2004. HIV/AIDS Surveillance Report, Cases of HIV infection and AIDS in the United States, volume 16. Available at: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2004report/pdf/2004SurveillanceReport.pdf (accessed 8 November 2014).
238. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology 2001; 34(2): 283–287.
239. Rai R, Wilson LE, Astemborski J et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002; 35(5): 1247–1255.
240. Barreiro P, Vispo E, Labarga P, Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis 2012; 32: 138–146.
241. Mohsen AH, Easterbrook P, Taylor CB, Norris S. Hepatitis C and HIV-1 coinfection. Gut 2002; 51: 601–608.
242. Soriano V, Sulkowski M, Bergin C et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel AIDS 2002; 16(6): 813–828.
243. Monga HK, Rodriguez-Barradas MC, Breaux K et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33(2): 240–247.
244. Soriano V, Vispo E, Fernandez-Montero JV, Labarga P, Barreiro P. Update on HIV/HCV coinfection. Curr HIV/AIDS Rep 2013; 10: 226–234.
245. Kim AY, Chung RT. Coinfection with HIV-1 and HCV—A one-two punch. Gastroenterology 2009; 137: 795–814.
246. Kim A, Lauer GM, Ouchi K et al. The magnitude and breadth of hepatitis C virus-specific CD8 + T cells depend on absolute CD4 + T cell count in individuals coinfected with HIV-1. Blood 2005; 105: 1170–1178.
247. Lambotin M, Barth H, Moog C et al. Challenges for HCV vaccine development in HIV-HCV coinfection. Expert Rev Vaccines 2012; 11: 791–804.
248. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008; 59: 473–485.
249. Soriano V. Section 1: hepatitis C: management of patients with HCV/HIV coinfection. In: Marcellin P, ed. Management of Patients with Viral Hepatitis. Paris: APMAHV, 2004: 109e36.
250. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015; 386: 1546–1555.
251. Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV coinfection among people living with HIV: A global systematic review and meta-analysis. Lancet Infec Dis 2016. doi:10.1016/S1473-3099(15)00485-5.
252. Easterbrook P, Platt L, Gower E, Razavi H, Sabin K, Vickerman P. Global systematic review and meta-analysis of the seroprevalence of HBV and HCV infection in HIV-infected persons. TUPEB 254 abstract. 8th IAS Conference on Pathogenesis, Treatment and Prevention, 19–22 July 2015, Vancouver, Canada.